It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study evaluated the bone regeneration capacity and mechanical properties of block-type hydroxyapatite (HA)/tricalcium phosphate (TCP) scaffolds in response to different concentrations of polydeoxyribonucleotide (PDRN) and recombinant human bone morphogenic protein 2 (rhBMP-2). Thirty-two male white rabbits were used as a model of calvarial bone defect and classified into eight groups according to type and concentration of growth factor administered, viz., control group (only HA/TCP scaffold), scaffold + PDRN (0.1, 1, 5, and 10 mg/mL each) and scaffold + rhBMP-2 (0.01, 0.05, and 0.1 mg/mL each). The specimens were evaluated using histomorphometric and radiological analyses. Histomorphometric analyses indicated that the administration of PDRN did not increase bone formation. However, significant increases in bone formation were observed with the administration of rhBMP-2 at 0.05 and 0.10 mg/mL on week 8 compared to the control (p < 0.05). Radiological analyses revealed a significant increase in bone formation at week 8 with the administration of PDRN at 5 mg/mL and 10 mg/mL, and rhBMP-2 at 0.05 or 0.10 mg/mL compared to the control (p < 0.05). Our findings show that block-type HA/TCP scaffolds possess sufficient mechanical strength and bone regeneration capacity when used with optimal concentrations of growth factors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Korea University Guro Hospital, Department of Oral & Maxillofacial Surgery, Seoul, Korea (GRID:grid.411134.2) (ISNI:0000 0004 0474 0479)
2 Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Department of Otorhinolaryngology-Head & Neck Surgery, Dongtan, Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964)
3 Sacred Heart Hospital, Hallym University College of Medicine, Department of Otorhinolaryngology-Head & Neck Surgery, Anyang, Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964)
4 R&D Center, Genoss, Suwon, Korea (GRID:grid.496466.f)
5 Sacred Heart Hospital, Hallym University College of Medicine, Department of Oral & Maxillofacial Surgery, Anyang, Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964); Hallym University, Graduate School of Clinical Dentistry, Chuncheon, Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964)
6 Seoul National University, Department of Oral & Maxillofacial Surgery, School of Dentistry, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
7 Sacred Heart Hospital, Hallym University College of Medicine, Department of Oral & Maxillofacial Surgery, Anyang, Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964); Hallym University, Graduate School of Clinical Dentistry, Chuncheon, Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964); Seoul National University, Department of Oral & Maxillofacial Surgery, School of Dentistry, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)